The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
|Articles|August 21, 2012
New Coupons Aim to Keep People Off Generic Drugs
Advertisement
If brand-name prescription medicines cost you as little as generic pills, which would you choose? A few drugmakers are betting Americans will stick with the name they know.
They've begun offering U.S. patients coupons to reduce copayments on brand-name medicines and compete with new generic versions of the drugs. The medicines include staples in the American medicine cabinet — cholesterol fighter Lipitor, blood thinner Plavix, and blood pressure drug Diovan — along with drugs for depression and breast cancer.
Read the full story:
Source: The Wall Street Journal/Associated Press
Advertisement
Related to this article
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Closing Reflections on the Future of Vitiligo Care
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
5